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Abstract
Background: Cardiac manifestations in COVID-19 are multifactorial and are associated with increased mortality. The clinical
utility and prognostic value of echocardiography in COVID-19 inpatients is not clearly defined. We aim to identify echocardiographic parameters that are associated with 30-day clinical outcomes secondary to COVID-19 hospitalization.
Methods: This retrospective cohort study was conducted in a large tertiary hospital in New York City during the COVID-19
pandemic. It included 214 adult inpatients with a laboratory-confirmed diagnosis of COVID-19 by reverse transcriptase polymerase chain reaction assay (RT-PCR) for SARS-CoV-2 on nasopharyngeal swab and had a transthoracic echocardiogram performed
during the index hospitalization. Primary outcome was 30-day all-cause inpatient mortality. Secondary outcomes were 30-day
utilization of mechanical ventilator support, vasopressors, or renal replacement therapy.
Results: Mild right ventricular systolic dysfunction (odds ratio (OR): 3.51, 95% confidence interval (CI): 1.63–7.57, p ¼ 0.001),
moderate to severe right ventricular systolic dysfunction (OR: 7.30, 95% CI: 2.20–24.25, p ¼ 0.001), pulmonary hypertension (OR:
5.39, 95% CI: 1.96–14.86, p ¼ 0.001), and moderate to severe tricuspid regurgitation (OR: 3.92, 95% CI: 1.71–9.03, p ¼ 0.001)
were each associated with increased odds of 30-day all-cause inpatient mortality. Pulmonary hypertension and moderate to severe
right ventricular dysfunction were each associated with increased odds of 30-day utilization of mechanical ventilator support and
vasopressors.
Conclusions: Right ventricular dysfunction, pulmonary hypertension, and moderate to severe tricuspid regurgitation were
associated with increased odds for 30-day inpatient mortality. This study highlights the importance of echocardiography and its
clinical utility and prognostic value for evaluating hospitalized COVID-19 patients.
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Introduction
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was first identified in December 2019
involving a cluster of pneumonia in the province of
Wuhan, China.1 New York City was disproportionately
affected by Coronavirus Disease 2019 (COVID-19) and
became the epicenter for the pandemic in the United
States of America. Within New York City, there were

greater than 230,000 cases and 19,000 confirmed deaths following a positive COVID-19 laboratory test.2
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Cardiac manifestations from COVID-19 include acute
cardiac injury, arrhythmias, acute coronary syndromes,
pericarditis, and myocarditis, and they are clinically relevant as they result in increased mortality.3,4 Other risk factors for mortality include older age, male sex, and medical
history of hypertension, diabetes, cardiovascular disease,
and chronic kidney disease, which are all associated with
increased mortality risk from COVID-19. Moreover, elevated cardiac troponin, C-reactive protein, and elevated
D-dimer are associated with reduced survival.5
Reports on cardiac imaging of COVID-19 patients are
emerging. One study showed that abnormal right ventricular longitudinal strain (RVLS) was an independent predictor of higher mortality in 120 COVID-19 patients.6 A study
of 110 COVID-19 patients found that right ventricular (RV)
enlargement was present in 31%, and this was associated
with increased mortality.7 Another study involving hospitalized non-intensive care unit (non-ICU) patients showed
that pulmonary hypertension was associated with a higher
rate of in-hospital mortality.8
As cardiac manifestations result in increased mortality in
COVID-19, echocardiography may assist in the early implementation of therapeutic interventions based on imaging
findings. Our primary aim is to identify echocardiographic
variables that are associated with 30-day all-cause mortality
in hospitalized COVID-19 patients. Our secondary aims are
to identify echocardiographic parameters associated with
mechanical ventilation use, vasopressors, and renal replacement therapy in hospitalized COVID-19 patients.
Identification of these echocardiographic findings may augment the evaluation and management of COVID-19 patients.

Methods
Study design and population
This was a retrospective cohort analysis of 214 consecutive
adult patients (ages 18 years old) admitted to the inpatient
setting at Maimonides Medical Center with a diagnosis of
COVID-19 between 1 March 2020 and 7 May 2020. This
tertiary care hospital treats a diverse patient population that
includes those of different race/ethnicities. Inclusion criteria
were laboratory positive reverse-transcriptase polymerase
chain reaction (RT-PCR) assay for SARS-CoV-2 in a respiratory tract sample and a transthoracic echocardiogram
study performed during the index inpatient hospitalization.
Five patients were excluded due to having non-diagnostic
echocardiograms. Only the initial echocardiography study
during the index hospitalization was included in the analysis. Ethical approval was obtained prior to the study from
our Medical Center Institutional Review Board.

Clinical data
Baseline patient demographic characteristics included age
(years), sex (male/female), race/ethnicity (White, Black,
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Asian, Hispanic, Other), body mass index (BMI obese),
and smoking status (no/yes). Medical history variables
included coronary artery disease (CAD), hypertension, diabetes mellitus, chronic obstructive pulmonary disease
(COPD), heart failure, atrial fibrillation, end-stage renal disease (ESRD), and cancer, all measured as no/yes. Laboratory
markers including peak creatinine, peak cardiac troponin I,
lymphocyte count, d-dimer, C-reactive protein (CRP), and
ferritin were reviewed. The treatments included the use of
hydroxychloroquine, tocilizumab, and remdesevir.

Transthoracic echocardiogram
All echocardiogram examinations were performed by
sonographers on a Philips Healthcare (Andover, MA)
iE33 or CX50 ultrasound system. All echocardiographic
images and data were independently analyzed and reviewed
by board certified echocardiographers based on current
American Society of Echocardiography (ASE) guidelines.
These findings were compared with the original clinical
reports and any discrepancies were adjudicated by a Level
III echocardiographer.
Left ventricular systolic function was graded by visual
estimation on two-dimensional (2D) images with the incorporation of endocardial border excursion, myocardial wall
thickening, and fractional shortening by 2D linear measurements when available. Left ventricular ejection fraction
(LVEF) greater than or equal to 51% was considered
normal, LVEF 41%–50% mildly reduced, LVEF 30%–
40% moderately reduced, and LVEF less than 30% was
categorized as severely reduced. Left ventricular enddiastolic dimension was measured in the parasternal longaxis views obtained perpendicular to the long axis at the
level of the mitral valve leaflet tips.9
RV size was measured in the apical 4 chamber or RV
focused view and considered enlarged if in end-diastole the
basal or mid-level diameter exceeded 41 mm or 35 mm,
respectively. RV systolic function was assessed qualitatively
on 2D images with incorporated visual recognition and
qualitative measures and graded as normal, mildly reduced,
or moderate to severely reduced based on free wall inward
movement, shortening of the RV in the long axis secondary
to contraction of the longitudinal fibers, and RV free wall
traction.6 RV systolic excursion velocity (S0 ) was measured
at the lateral annulus of the tricuspid valve by pulsed wave
tissue Doppler interrogation.10
Pulmonary arterial systolic pressure (PASP) was determined by assessing peak tricuspid regurgitation (TR) velocity with continuous wave Doppler and right atrial pressure
(RAP) based on inferior vena cava (IVC) size. PASP was
calculated by using the simplified Bernoulli’s equation [4
(TR)2 þ RAP]. In non-mechanically ventilated patients,
RAP was assumed to be 3 mmHg with IVC size less than
2.1 cm and respiratory variation greater than 50%,
15 mmHg if IVC was greater than 2.1 cm with respiratory
variation less than 50%, and otherwise considered 8 mmHg
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if it did not meet either criteria. The presence of pulmonary
hypertension was defined by a PASP greater than
35 mmHg. In the setting of an incomplete TR jet velocity
or indeterminate RAP, a TR velocity greater than 2.8 m/s
was also considered to be positive for the presence of pulmonary hypertension.
Valvular regurgitation for aortic, mitral, tricuspid, and
pulmonary valves was classified by severity based on qualitative assessment via color Doppler and continuous wave
Doppler when available. Vena contracta width, flow convergence, jet area, and spectral wave density were used as
supplemental measures when available to determine valvular regurgitation severity.11
LV diastolic function was defined by the incorporation of
pulsed wave Doppler interrogation between the mitral leaflet
tips to determine the peak modal velocity in early diastole
(E-wave) and late diastole (A-wave) at the leading edge of
the spectral waveform for E/A ratio, tissue Doppler interrogation of the lateral and septal basal regions for e’ velocity,
average E/e’ ratio, TR velocity, and left atrial volume index
(LAVI) as per the ASE guidelines.12 Left atrial volumes (LAV)
were measured in the apical views at the end of LV systole
using the biplane disk summation technique with incorporation of body surface area (BSA) to obtain the LAVI.

Study outcomes
The primary outcome was 30-day all-cause inpatient mortality. Secondary outcomes were utilization of mechanical
ventilator support, intravenous vasopressors, or renal
replacement therapy within 30 days during the index hospitalization. All-cause mortality was defined by death due to
any etiology within 30 days during hospitalization for
COVID-19. Mechanical ventilator support was defined by
respiratory failure and the need for endotracheal intubation.
Utilization of intravenous vasopressors was defined by the
use of any vasoactive agents including intravenous norepinephrine, phenylephrine, vasopressin, dopamine, or epinephrine. Renal replacement therapy was defined by
kidney failure requiring hemodialysis or continuous renal
replacement therapy. All patients were evaluated for an outcome event within 30 days of the admission date to the
hospital. Patient outcomes that did not achieve 30-day criteria were excluded from the analysis. The final follow-up
date was 24 May 2020.

Statistical analysis
Descriptive statistics of mean and standard deviation were
used to describe the continuous variables. Frequency and
percentage were used to describe the categorical variables.
Multivariable binary logistic regression analysis for the outcome variables was conducted for each of the 13 echocardiographic predictor variables while simultaneously adjusting
for age, sex, coronary artery disease, hypertension, diabetes
mellitus, and chronic obstructive pulmonary disease.
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All significant binary logistic regression multivariable analyses had the Hosmer and Lemenshow goodness-of-fit test and
the C-statistic reported. All p-values were two-tailed. Alpha
level for significance was p < 0.05. IBM SPSS Statistics
Version 26 was used for all analyses (IBM, 2019).

Results
Table 1 describes the sample characteristics. Mean age of
the sample was 66.5 (SD ¼ 16.51). There were 63.1% male
and 48.6% of a minority race/ethnicity origin. The sample
had multiple co-morbidities with 68.2% of the cohort with
hypertension, 36.4% with diabetes mellitus, 24.8% with coronary artery disease, and 12.1% with history of COPD. All
Table 1. Sample characteristics of the 214 COVID-19 patients.
Variables
Demographics
Age (years), mean
Sex (male)
Race/Ethnicity
White
Black
Asian
Other
Hispanic
BMI (obese) (n ¼ 170)
Smoking (yes) (n ¼ 125)
Medical history
Coronary artery disease (yes)
Hypertension (yes)
Diabetes mellitus (yes)
COPD (yes)
Heart failure (yes)
Atrial fibrillation (yes)
ESRD (yes) (n ¼ 213)
Cancer (yes) (n ¼ 213)
Laboratory values-mean (SD)
Creatinine (mg/dl)
Troponin I (ng/ml) (n ¼ 202)
Lymphocyte count (%) (n ¼ 213)
D-dimer (DDU ng/ml) (n ¼ 161)
CRP (mg/dl) (n ¼ 206)
Ferritin (ng/ml) (n ¼ 198)
COVID-19 treatments
Hydroxycholoroquine (yes)
Tocilizumab (yes)
Remdesivir (yes)
30-day outcomes
All-cause mortality (yes) (n ¼ 210)
Renal replacement therapy (yes) (n ¼ 211)
Vasopressor (yes)
Ventilator (yes)

Mean (SD) or
frequency (%)
66.5 (16.51)
135 (63.1)
110
23
30
23
28
69
28

(51.4)
(10.7)
(14.0)
(10.7)
(13.1)
(32.2)
(13.1)

53
146
78
26
18
43
9
23

(24.8)
(68.2)
(36.4)
(12.1)
(8.4)
(20.1)
(4.2)
(10.7)

3.2
2.9
13.7
1574.6
22.3
1528.2

(2.96)
(11.02)
(9.87)
(1355.90)
(13.68)
(1920.60)

160 (74.8)
38 (17.8)
24 (11.2)
91
61
116
118

(42.5)
(28.5)
(54.2)
(55.1)

Note: The median value for creatinine was 1.9 and for D-dimer was 927.0. SD:
standard deviation; BMI: body mass index; CABG: coronary artery bypass
grafting; COPD: chronic obstructive pulmonary disease; ESRD: end-stage renal
disease; CRP: C-reactive protein; ICU: intensive care unit.
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mean laboratory values including troponin-I, creatinine,
lymphocyte count, D-dimer, CRP, and ferritin were elevated and above normal laboratory range limits. With regard
to treatments, nearly 75% of the sample received hydroxychloroquine treatment.
Table 2. Echocardiographic variables.
Variables
Left ventricular systolic function
Normal
Mildly reduced
Moderately reduced
Severely reduced
Left ventricular EDD (mean)
Right ventricular systolic function
Normal
Mildly reduced
Moderate to severely reduced
Indeterminate
Right ventricular size
Enlarged
Indeterminate
Right ventricular S0 [mean]
Pulmonary hypertension
Present
Indeterminate
Left ventricular diastolic function
Normal
Grade 1 diastolic dysfunction
Grade 2 diastolic dysfunction
Grade 3 diastolic dysfunction
Unknown or indeterminate
Mitral regurgitation
None
Mild
Moderate to severe
Indeterminate
Aortic regurgitation
None
Mild
Moderate to severe
Indeterminate
Tricuspid regurgitation
None
Mild
Moderate to severe
Indeterminate
Pulmonic regurgitation
None
Mild
Moderate to severe
Indeterminate
Left atrial volume index (mean)
Pericardial effusion
Present
Indeterminate
EDD: end diastolic dimension.

Mean (SD) or
frequency (%)
157
31
12
14
4.4

(73.4)
(14.5)
(5.6)
(6.5)
(0.69)

150
41
20
3

(70.1)
(19.2)
(9.3)
(1.4)

72 (33.6)
11 (5.1)
13.1 (3.35)
75 (35.0)
107 (50.0)
35
72
12
11
84

(16.4)
(33.6)
(5.6)
(5.1)
(39.3)

150
43
19
2

(70.1)
(20.1)
(8.9)
(0.9)

169
27
17
1

(79.0)
(12.6)
(7.9)
(0.5)

97
70
44
3

(45.3)
(32.7)
(20.6)
(1.4)

125
38
11
35
34.0

(58.4)
(17.8)
(5.1)
(16.4)
(19.39)

22 (10.3)
5 (2.3)
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The median time from date of admission to performance
of echocardiography study was three days. Table 2 describes
the echocardiographic variables. RV enlargement was identified in greater than one-third (33.6%) with RV systolic
dysfunction present in 28.5%. Additionally, the presence
of pulmonary hypertension was identified in 35.0%. The
mean value of RV S’ mean (13.1 cm/s) was within normal
limits but not all patients were within normal limits. Left
ventricular systolic dysfunction was identified in 26.6%.
The mean left ventricular end-diastolic dimension size was
normal. With regard to diastology, the highest prevalence
was Grade I diastolic dysfunction. Among valvular regurgitation, the highest prevalence was tricuspid regurgitation,
which was present in 53.3% and with 20.6% having moderate to severe tricuspid regurgitation. A pericardial effusion was seen in 10.3%.
There were 91 deaths (42.5%) that occurred within 30
days of the index hospitalization (Table 1). Table 3 shows
multivariable logistic regression analyses for 30-day allcause mortality. The presence of mildly reduced RV systolic
function (OR: 3.51, 95% CI: 1.63–7.57, p ¼ 0.001), moderate to severely reduced RV systolic function (OR: 7.30, 95%
CI: 2.20–24.25, p ¼ 0.001), pulmonary hypertension (OR:
5.39, 95% CI: 1.96–14.86, p ¼ 0.001), and moderate to
severe tricuspid regurgitation (OR: 3.92, 95% CI: 1.71–
9.03, p ¼ 0.001) were each significantly associated with
higher odds for mortality.
Most patients were critically ill as more than half of the
cohort required mechanical ventilator support (55.1%) or
vasopressor utilization (54.2%) within 30 days. Noninvasive ventilation of high-flow nasal cannula was utilized
by 28.5% (n ¼ 61) and 22.9% (n ¼ 49) began with high-flow
nasal cannula and then transitioned to mechanical ventilator support. Additionally, 28.5% of the patients required
renal replacement therapy (Table 1). Table 4 shows multivariable logistic regression analyses for 30-day utilization of
mechanical ventilator support, vasopressors, or renal
replacement therapy. Moderate to severely reduced RV systolic function (OR: 3.49, 95% CI: 1.08–11.29, p ¼ 0.04) and
pulmonary hypertension (OR: 3.96, 95% CI: 1.33–11.75,
p ¼ 0.01) were each significantly associated with higher
odds for ventilator use. Mildly reduced RV systolic function
(OR: 2.26, 95% CI: 1.06–4.85, p ¼ 0.04), moderate to
severely reduced RV systolic function (OR: 3.69, 95% CI:
1.19–11.41, p ¼ 0.02), and pulmonary hypertension
(OR:4.88, 95% CI: 1.69–14.09, p ¼ 0.003) were each significantly associated with higher odds for vasopressor use.
Moderately reduced left ventricular systolic function (OR:
4.17, 95% CI: 1.12–15.53, p ¼ 0.03), severely reduced left
ventricular systolic function (OR: 3.44, 95% CI: 1.05–
11.27, p ¼ 0.04), moderate to severe tricuspid regurgitation
(OR: 6.63, 95% CI: 2.58–17.02, p  0.001), mildly reduced
RV systolic function (OR: 3.11, 95% CI: 1.43–6.74,
p ¼ 0.004), moderate to severely reduced RV systolic function (OR: 7.71, 95% CI: 2.56–23.22, p < 0.001), and
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Table 3. Multivariable logistic regression analyses for 30-day all-cause inpatient mortality.
Variables
Left ventricular systolic function
Normal
Mildly reduced
Moderately reduced
Severely reduced
Left ventricular EDD
Right ventricular systolic function
Normal
Mildly decreased
Moderate to severely reduced
Right ventricular size (enlarged)
Right ventricular S0
Pulmonary hypertension (present)
Left ventricular diastolic function
Normal
Grade 1 diastolic dysfunction
Grade 2 diastolic dysfunction
Grade 3 diastolic dysfunction
Mitral regurgitation
None
Mild
Moderate to severe
Aortic regurgitation
None
Mild
Moderate to severe
Tricuspid regurgitation
None
Mild
Moderate to severe
Pulmonic regurgitation
None
Mild
Moderate to severe
Left atrial volume index
Pericardial effusion (present)

Mortality

OR (95% CI)

p-value

H

C

–
1.00
2.11
2.37
2.40
1.21

(0.90,
(0.63,
(0.71,
(0.74,

4.94)
8.91)
8.05)
1.95)

0.09
0.20
0.16
0.45

1.00
3.51
7.30
1.76
0.89
5.39

(1.63,
(2.20,
(0.94,
(0.79,
(1.96,

7.57)
24.25)
3.28)
1.004)
14.86)

0.001
0.001
0.08
0.06
0.001

1.00
0.62 (0.21, 1.81)
0.41 (0.08, 2.23)
1.04 (0.21, 5.15)

–
0.91 0.73

–
–
0.17 0.74
–

0.38
0.30
0.97
–

1.00
1.18 (0.56, 2.46)
1.30 (0.48, 3.56)

0.67
0.61
–

1.00
1.44 (0.59, 3.51)
1.26 (0.43, 3.65)

0.43
0.67
0.06 0.71

1.00
1.56 (0.79, 3.06)
3.92 (1.71, 9.03)

0.20
0.001
–

1.00
1.44
0.82
1.01
1.32

(0.64,
(0.22,
(0.99,
(0.52,

3.23)
3.15)
1.02)
3.40)

0.38
0.78
0.60
0.56

–
–

Note: All multivariable analyses adjust for age, sex, coronary artery disease, hypertension, diabetes mellitus, and chronic obstructive
pulmonary disease. Analyses classifying all missing data for pulmonary hypertension as absence of pulmonary hypertension also
showed significantly increased odds for those with pulmonary hypertension (OR: 3.42, 95% CI: 1.79, 6.51, p < 0.001, H ¼ 0.65,
c ¼ 0.71). OR: odds ratio; CI: confidence interval; EDD: end diastolic dimension; H: Hosmer and Lemenshow goodness-of-fit test;
C: C statistic.

enlarged RV size (OR: 3.11, 95% CI: 1.58–6.12, p ¼ 0.001)
were each significantly associated with higher odds for renal
replacement therapy.

Discussion
We found RV systolic dysfunction regardless of severity had
increased odds for 30-day all-cause mortality. In addition,
the risk was proportional to the degree of RV dysfunction
with moderate to severe RV systolic dysfunction resulting in
higher odds than mild RV dysfunction. For secondary outcomes, any degree of RV systolic dysfunction was associated with increased odds for utilization of vasopressors and

renal replacement therapy. Pulmonary hypertension was
also associated with adverse 30-day clinical outcomes of
increased odds for all-cause inpatient mortality, need for
mechanical ventilation, and vasopressor utilization.
Moderate to severe tricuspid regurgitation was associated
with increased odds for 30-day all-cause mortality and renal
replacement therapy (see Fig. 1).
Acute right heart failure or systolic dysfunction can
occur due to increased RV afterload or decreased RV contractility.13 COVID-19 is often associated with chest CT
scans findings of bilateral multilobar ground-glass opacifications14 and associated hypoxic respiratory failure, which
can increase RV afterload. In addition, COVID-19 may

0.49
0.72

0.09
0.59
0.56
0.52

1.00
1.28 (0.64, 2.57)
1.16 (0.52, 2.63)
1.00
0.49
0.68
1.01
1.39
1.13)
2.69)
1.03)
3.71)

0.45
0.12

1.00
0.70 (0.28, 1.76)
0.41 (0.13, 1.27)

(0.21,
(0.17,
(0.99,
(0.52,

0.11
0.10

0.27
0.04
0.22
0.25
0.01

1.00
0.53 (0.24, 1.15)
0.39 (0.13, 1.19)

3.35)
11.29)
2.88)
1.19)
11.75)

0.79
0.25
0.70
0.95

0.83
0.64
0.41

(0.71,
(1.08,
(0.79,
(0.96,
(1.33,

1.00
1.55
3.49
1.50
1.07
3.96

2.70)
8.51)
2.68)
1.61)

1.00
1.12 (0.38, 3.30)
0.67 (0.12, 3.66)
0.51 (0.10, 2.53)

(0.47,
(0.57,
(0.23,
(0.60,

1.00
1.13
2.20
0.78
0.98

p-value

C

–
–

–

–

–

–

–
–
0.29 0.83
–

–
0.18 0.75

–

H

(1.06,
(1.19,
(0.96,
(0.95,
(1.69,

(0.56,
(0.93,
(0.38,
(0.66,

4.85)
11.41)
3.37)
1.17)
14.09)

2.98)
16.05)
4.26)
1.70)

1.00
0.58
0.66
1.00
1.84

(0.26,
(0.18,
(0.98,
(0.71,

1.30)
2.49)
1.02)
4.81)

1.00
1.64 (0.84, 3.21)
1.66 (0.75, 3.68)

1.00
0.67 (0.28, 1.64)
1.05 (0.36, 3.09)

1.00
0.68 (0.32, 1.42)
0.67 (0.24, 1.87)

1.00
0.89 (0.32, 2.52)
0.47 (0.09, 2.48)
0.62 (0.13, 2.92)

1.00
2.26
3.69
1.80
1.05
4.88

1.00
1.29
3.87
1.27
1.06

Vasopressor
OR (95% CI)

0.19
0.54
0.95
0.21

0.15
0.21

0.38
0.93

0.30
0.45

0.83
0.47
0.54

0.04
0.02
0.07
0.33
0.003

0.55
0.06
0.70
0.81

p-value

C

–
–

–

–

–

–

–
–
0.02 0.81
–

–
0.43 0.69

–

H

(1.43,
(2.56,
(1.58,
(0.79,
(0.85,

(0.51,
(1.12,
(1.05,
(0.65,

6.74)
23.22)
6.12)
1.01)
7.24)

3.27)
15.53)
11.27)
1.78)

1.00
1.67
2.98
1.01
1.33

(0.67,
(0.73,
(0.99,
(0.48,

4.15)
12.16)
1.03)
3.69)

1.00
1.95 (0.90, 4.22)
6.63 (2.58, 17.02)

1.00
0.70 (0.23, 2.09)
0.69 (0.20, 2.37)

1.00
0.69 (0.29, 1.65)
1.01 (0.32, 3.14)

1.00
1.02 (0.31, 3.30)
1.58 (0.24, 10.34)
2.14 (0.40, 11.48)

1.00
3.11
7.71
3.11
0.89
2.48

1.00
1.29
4.17
3.44
1.08

Renal RT
OR (95% CI)

0.27
0.13
0.33
0.58

0.09
<0.001

0.52
0.56

0.40
0.99

0.98
0.63
0.37

0.004
<0.001
0.001
0.07
0.10

0.59
0.03
0.04
0.77

p-value

C

–
–

–

0.64 0.74

–

–

0.38 0.73
–
–
–

–
0.88 0.75

0.88 0.70

H
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Note: All multivariable analyses adjust for age, sex, coronary artery disease, hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. Analyses classifying all missing data for pulmonary
hypertension as absence of pulmonary hypertension showed significantly increased odds for those with pulmonary hypertension for ventilator (OR: 2.30, 95% CI: 1.17, 4.52, p ¼ 0.02, H ¼ 0.19, c ¼ 0.75),
vasopressor (OR: 2.58, 95% CI: 1.34, 4.97, p ¼ 0.01, H ¼ 0.99, c ¼ 0.70), renal replacement therapy (OR: 3.10, 95% CI: 1.55, 6.20, p ¼ 0.001). OR: odds ratio; CI: confidence interval; RT: replacement therapy;
EDD: end diastolic dimension; H: Hosmer and Lemenshow goodness-of-fit test; C: C statistic.

Left ventricular
systolic function
Normal
Mildly reduced
Moderately reduced
Severely reduced
Left ventricular EDD
Right ventricular systolic function
Normal
Mildly reduced
Moderate to severely reduced
Right ventricular size (enlarged)
Right ventricular S0
Pulmonary hypertension (present)
LV diastolic function
Normal
Grade 1 dysfunction
Grade 2 dysfunction
Grade 3 dysfunction
Mitral regurgitation
None
Mild
Moderate to severe
Aortic regurgitation
None
Mild
Moderate to severe
Tricuspid regurgitation
None
Mild
Moderate to severe
Pulmonic regurgitation
None
Mild
Moderate to severe
Left atrial volume index
Pericardial effusion (present)

Ventilator
OR (95% CI)

|

Variables

Table 4. Multivariable logistic regression for 30-day ventilator use, vasopressor use, and renal replacement therapy.
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Fig. 1. Echocardiographic variables associated with 30-day all-cause inpatient mortality. Forest plot of echocardiographic variables associated
with 30-day all-cause inpatient mortality. All multivariable analyses adjust for age, sex, coronary artery disease, hypertension, diabetes mellitus,
and chronic obstructive pulmonary disease. CI: confidence interval.

predispose patients to having venous thrombotic events,
including pulmonary embolism, which may further increase
RV afterload.15 RV dysfunction compromises cardiac
output, and the shifting of the interventricular septum
towards the left can compromise LV diastolic filling and
reduce systemic output.16 This reduced cardiac output
may help explain the increased odds for vasopressors.
This may also contribute to renal hypoperfusion. In addition, as RV dysfunction progresses, there is usually a rise in
central venous pressure and subsequent rise in renal venous
pressure which may reduce GFR.17 This may explain why
we found that any degree of RV systolic dysfunction was
associated with an increased odds for both vasopressor support and renal replacement therapy. Additionally, approximately one-third of our cohort had RV enlargement. We
found that RV enlargement was independently associated
with renal replacement therapy. A previous study of 110
COVID-19 patients with RV enlargement reported an association with increased mortality.7 We did not show an association between RV enlargement and mortality with our
larger sample size. This suggests that further studies are
needed before one can conclude that RV enlargement is
associated with increased mortality.
There is concern that patients with COVID-19 develop
ARDS.18 RV systolic dysfunction is independently shown
to be associated with worse outcomes in patients with
ARDS.19 In our cohort, moderate to severe RV systolic
dysfunction was associated with increased odds for mechanical ventilator support. In ARDS, the key reasons for RV
dysfunction include elevated pulmonary vascular resistance
secondary to imbalance between vasodilators and vasoconstrictors, hypoxic pulmonary vasoconstriction, endothelial
injury, thrombosis, and possibly contractile impairment.20
There may be a role of inflammation as well in the development of RV dysfunction with IL-6 being associated with
RV dysfunction.21 Higher IL-6 is associated with RV dysfunction independent of pulmonary vascular disease burden
in pulmonary arterial hypertension. Thus, the inflammatory
storm caused by COVID-19 may also contribute to RV
dysfunction.22

Pulmonary hypertension was also associated with
adverse 30-day clinical outcomes of increased odds for allcause inpatient mortality, vasopressor utilization, and need
for mechanical ventilator support. However, one of the limitations of PASP assessment on echocardiography is that
non-physiologic TR jets (<0.8 m/s) and incomplete
Doppler envelopes due to a lack of significant TR were
excluded from the initial analysis unless the TR velocity
was greater than 2.8 m/s. In addition, patients with
unknown RAP in the setting of being mechanically ventilated were excluded in our primary analysis unless the TR
velocity was greater than 2.8 m/s. We then performed an
additional analysis by imputing that all patients who had an
incomplete TR Doppler envelope or unknown RAP in the
setting of TR velocity <2.8 m/s as having an absence of
pulmonary hypertension. Our findings remained consistent
with the original analysis as pulmonary hypertension continued to be associated with an increased odds for the
adverse 30-day clinical outcomes.
Pulmonary hypertension has important prognostic value
and is an independent predictor of mortality in cardiac conditions including chronic left heart failure23 and is associated with reduced functional status and worse outcomes in
chronic lung disease.24 We suspect pulmonary hypertension
in patients with COVID-19 is likely multifactorial and may
be related to ventilation perfusion mismatch in the setting of
significant hypoxic respiratory failure and acute respiratory
distress syndrome, increased pulmonary vascular tone in the
setting of inflammatory state, and presence of microthrombi
or pulmonary embolism in the lungs. Recent autopsy studies with COVID-19 patients noted evidence of pulmonary
microthrombi,18 which can lead to increased pulmonary
artery systolic pressure and eventually RV failure. Further
investigation is warranted in regard to the extent of pulmonary hypertension in COVID-19 patients and the etiology
for such occurrences.
In a single-center, observational, cross-sectional study,
involving hospitalized non-ICU patients, another study
also showed that pulmonary hypertension was associated
with a higher rate of in-hospital mortality. However, they
did not establish RV dysfunction to be associated with these
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findings. They defined RV dysfunction by reduced tricuspid
annular plane systolic excursion or RV S’.25 Mean RV S’ in
our study was 13.1 cm/s, which was also within normal
limits, and was not identified to be significantly associated
with any of the 30-day clinical outcomes. While RV S’ is
often used as a surrogate marker for RV systolic function, it
is a reflection of contractility of the RV basal lateral segment10 and mostly reflects longitudinal myocardial contraction. It does not take into consideration radial and
circumferential fiber shortening. As a result, it may not correlate with RV dysfunction involving the mid to apical or
septal RV segments. Furthermore, RV dysfunction in the
setting of pulmonary embolism often does not involve the
basal segment.8 RV longitudinal strain from 2D speckletracking echocardiography is likely a more accurate estimate of RV systolic function. Abnormal RVLS has been
shown to be an independent predictor of higher mortality
in COVID-19 patients.6 Also, in a smaller cohort of 115
patients with COVID-19 pneumonia, elevated mean pulmonary arterial pressure and RV dysfunction were each associated with higher risk for in-hospital mortality.26 This
finding for COVID-19 pneumonia is similar to our finding
for COVID-19 patients of RV dysfunction associated with
increased odds for mortality. We suggest careful monitoring
of RV dysfunction in COVID-19 patients.
Moderate to severe tricuspid regurgitation was observed
in approximately 20% of patients in this cohort and was
associated with an increased odds for mortality and need for
renal replacement therapy. In addition, RV enlargement
was associated with an increased need for renal replacement
therapy. Reduced RV stroke volume results in RV enlargement and subsequent increase in tricuspid regurgitation.13
We suggest that tricuspid regurgitation was functional in
the setting of RV enlargement, RV dysfunction and pulmonary hypertension.
Moderate to severe LV systolic dysfunction was only associated with an increased need for renal replacement therapy.
Left ventricular dysfunction can lead to the development of
kidney injury and is classified as cardiorenal syndrome type
1.27 This is associated with adverse outcomes, including mortality.28 We did not identify any association with 30-day mortality, need for mechanical ventilation or vasopressor use. We
suggest that our lack of significance may be due to small
sample size. Diastolic dysfunction was also not statistically
associated with any of the 30-day clinical outcomes. In addition, the highest prevalence was Grade I diastolic dysfunction
with impaired LV relaxation but normal LV filling pressures,
which is not unexpected considering that the mean age of our
sample was approximately 66 years.

Limitations
There are several limitations. First, due to the COVID-19
pandemic and to ensure sonographer safety, our echocardiography laboratory had a modified, focused transthoracic
echocardiogram protocol. For example, quantitative
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valvular stenosis was not assessed on the majority of studies.
In addition, ultrasound contrast enhancing agents were not
administered in the majority of patients to minimize acquisition time for the sonographers in the setting of COVID-19.
Second, some patients were placed in the prone position due
to advanced respiratory failure, and thus could not have an
echocardiogram study performed. Third, this was a retrospective analysis with data obtained at a single center, and
echocardiograms were only performed on patients that had
requests placed by the primary providers. As a result, we
cannot exclude selection bias. Fourth, RV longitudinal
strain by 2D speckle tracking to objectively assess RV systolic function was not performed. Fifth, although we had
many significant associations which suggests that for those
associations that the study was adequately powered, it is
possible that our non-significant associations were not adequately powered. Sixth, this is a cross-sectional study that
can only report associations of variables. A clinical trial is
necessary to determine if our predictors lead to and cause the
outcomes. Seventh, obesity and tobacco use are known risk
factors for adverse outcomes. However, due to unknown
data in many patients, we could not adjust for these factors
in our analyses. Eighth, we did not have the exact time the
laboratory variables were obtained and included laboratory
variables to describe the sample.

Conclusion
In patients with COVID-19, we found that any degree of RV
systolic dysfunction, pulmonary hypertension, and moderate
to severe tricuspid regurgitation were each associated with
increased odds for 30-day all-cause inpatient mortality.
This study highlights the importance of echocardiography
and its clinical utility and prognostic value in the evaluation
of hospitalized COVID-19 patients. Echocardiography in
COVID-19 patients may help identify patients that may benefit from earlier implementation of therapeutic interventions
such as antivirals, immunomodulators, anticoagulation, and/
or convalescent plasma.
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